Infusions of interleukin-1? after autologous transplantation for Hodgkin's disease and non-Hodgkin's lymphoma induce effector cells with antilymphoma cytolytic activity

1994 ◽  
Vol 14 (3) ◽  
pp. 205-211 ◽  
Author(s):  
Emmanuel Katsanis ◽  
Daniel J. Weisdorf ◽  
Zhiyi Xu ◽  
Betsy B. Dancisak ◽  
Mary L. Halet ◽  
...  
Keyword(s):  
Hodgkin's Disease ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin’S Disease ◽  
Interleukin 1 ◽  
Autologous Transplantation ◽  
Cytolytic Activity ◽  
Hodgkin's Lymphoma ◽  
Effector Cells ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

scholarly journals Hodgkin's disease and non-hodgkin's lymphoma containing reed-sternberg-like giant cells in Taiwan: A clinicopathologic analysis of 50 cases

Cancer ◽  
2010 ◽  
Vol 69 (5) ◽  
pp. 1254-1258 ◽  
Author(s):  
Ruey-Long Hong ◽  
Ih-Jen Su ◽  
Yao-Chang Chen ◽  
Hong-Chong Hsieh ◽  
Chiu-Hwa Wang ◽  
...  
Keyword(s):  
Hodgkin's Disease ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin’S Disease ◽  
Giant Cells ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma.

1992 ◽  
Vol 10 (11) ◽  
pp. 1682-1689 ◽  
Author(s):  
H M Lazarus ◽  
P Crilley ◽  
N Ciobanu ◽  
R J Creger ◽  
R M Fox ◽  
...  
Keyword(s):  
Hodgkin's Disease ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin’S Disease ◽  
Autologous Bone Marrow Transplantation ◽  
Autologous Bone Marrow ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Autologous Bone ◽  
Disease Free

PURPOSE We determined the toxicity and efficacy of a new preparative autologous bone marrow transplantation (ABMT) regimen in patients with relapsed or refractory non-Hodgkin's lymphoma or Hodgkin's disease. PATIENTS AND METHODS Forty-four non-Hodgkin's lymphoma and 35 Hodgkin's disease patients 16 to 63 years of age were given intravenous carmustine (BCNU) 600 to 1,050 mg/m2, etoposide 2,400 to 3,000 mg/m2, and cisplatin 200 mg/m2 (BEP) and ABMT. Fifty-nine patients also received 15 to 20 Gy local radiation (involved-field radiotherapy [RI]) to active or previously bulky (> 5 cm) disease sites. RESULTS Nonhematologic toxicities included nausea, vomiting, high-tone hearing loss, stomatitis, esophagitis, diarrhea, and hepatic and pulmonary toxicity. Two patients died within 40 days of marrow infusion as a result of sepsis and one patient died 7 months after transplant as a result of pulmonary fibrosis. Complete remissions (CRs) were noted in 72% (n = 57) of patients (n = 33 non-Hodgkin's lymphoma; n = 24 Hodgkin's disease). Forty patients (51%) remained alive and disease-free (n = 24 non-Hodgkin's lymphoma; n = 16 Hodgkin's disease) at a median of 17 (range, 8 to 57) months after marrow reinfusion. CONCLUSIONS This regimen seems to be effective for relapsed lymphoma patients whose disease continues to exhibit chemotherapy sensitivity (16 of 24 [67%] disease-free). Furthermore, this regimen seems to be effective in patients who have never attained a CR (seven of 19 [37%] disease-free).

scholarly journals Non-Hodgkin's lymphoma after prolonged remission of Hodgkin's disease in an HTV-infected patient

1991 ◽  
Vol 2 (8) ◽  
pp. 585-587 ◽  
Author(s):  
C. Montalban ◽  
C. Bellas ◽  
J.L. Rodriguez-Garcia ◽  
M. Aguado ◽  
R. Fernandez-Muñoz
Keyword(s):  
Hodgkin's Disease ◽  
Infected Patient ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin’S Disease ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma
Sign in / Sign up

Export Citation Format

Share Document